Free Webinar Tomorrow, November 19: Ketamine, Psilcobyin and New Drug Therapies (Half 2)

In case you missed the first webinar, you can SEE IT HERE.

For the past decade, Harris Bricken attorneys have advised national and international corporations and entrepreneurs on rapidly evolving laws and regulations in the cannabis, hemp, and regulated substances industries.

Over the past several years, our attorneys have been leaders in advising investors, companies, and entrepreneurs on new drug therapies – psilocybin, ketamine infusion clinics, MDMA, and other psychedelic substances. We already discussed these topics live on July 9th and will now hold a follow-up webinar by popular demand.

On Thursday, November 19, 2020 at 12 p.m. PT, Harris Bricken’s attorneys will discuss the election results and other recent developments related to psychedelics and emerging drug therapies. We will examine the process and outcomes for Measure 109 (psilocybin licensing) and Measure 110 (decriminalizing controlled substances) in Oregon, as well as future efforts to decriminalize, protect, and regulate the use of psychedelic drugs. The conversation will cover everything from religious exceptions to commercial opportunities.

The panel will be moderated by Vince Sliwoski (Portland) with the panelists Griffen Thorne (Los Angeles), Alison Malsbury (San Francisco) and Jesse Mondry (Portland). Panellists will ask questions during the presentation.

Leave a Comment